Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499792 | 0.76 | CNR1 (0.33) | PTGS2CA1CA2CA4CA5A | |
| SCHEMBL24499800 | 0.68 | LOXL2 (0.34) | PTGS2CA1CA2CA4CA5A | |
| SCHEMBL24499797 | 0.68 | — | — | |
| SCHEMBL10220328 | 0.68 | NOS1 (0.44) | CNR1CNR2 | |
| SCHEMBL24499806 | 0.67 | CA1 (0.44) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL10227008 | 0.66 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL21718699 | 0.64 | CNR1 (0.31) | PTGS2CNR1CNR2 | |
| SCHEMBL21721523 | 0.64 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL18643280 | 0.64 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL24499799 | 0.64 | HRH1 (0.30) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | PTGS2 2171/4885CA1 419/4885CA2 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.